- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04221360
A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-375
A Randomized, Open-label, Single-dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability After Oral Administration of High Dose CKD-375 and D390 in Healthy Adults.
Study Overview
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Min Soo Park, M.D., Ph.D.
- Phone Number: +82-2-2228-0401
- Email: minspark@yuhs.ac
Study Locations
-
-
-
Soeul, Korea, Republic of
- Yonsei University Severance Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy adult who is 19 ~ 55 years at the time of screening
- Body weight more than 55 kg for male and more than 50kg for female
- BMI more than 18.5 kg/m2 or less than 27.0 kg/m2
- Females must be menopause or surgical infertility
- Males who have consented to the use of appropriate pregnancy contraceptive methods up to 28 days after the last investigational product and not to provide sperm
- Subjects who voluntarily decided to participate and informed consent based upon understanding on the study.
Exclusion Criteria:
- Subjects who have a history of clinically significant hepatic, renal, nervous, immune, respiratory, urinary, digestion, endocrine, hemato-oncology, cardiovascular systemic disease or psychosis disorder
- Subjects who has clinically significant dehydration or is vulnerable to dehydration due to poor oral intake
- Subjects who underwent intravenous administration of radioactive iodine contrast agents (e.g., intravenous urography, venous cholangiography, angiography, computed tomography using contrast agents, etc.) within 48 hours prior to the first dose of the investigational product
- Subjects who have a significant urinary tract infection or have such a history
- Subjects who have genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
- Subjects who have a history of gastrointestinal disorders (Crohn's disease, ulcerative colitis, etc.) or surgery (except simple appendectomy or hernia surgery) that may affect the absorption of the drug
- Subjects who have a history of clinically significant hypersensitivity to drugs or additives, including components of the investigational product (empagliflozin, metformin)
Subjects who are deemed unsuitable as subjects in the screening test performed within 28 days before the administration of investigational product
- AST, ALT> UNL(Upper Normal Limit)x1.25
- Total bilirubin > UNL(Upper Normal Limit)x1.5
- eGFR (Estimated Glomerular Filtration Rate) <60 mL / min / 1.73m2 using the MDRD (Modification of Diet in Renal Disease) formula
- Positive immunologic serological tests (hepatitis B test, hepatitis C test, human immunodeficiency virus (HIV) test, syphilis test)
- After resting for more than 5 minutes, systolic blood pressure> 150 mmHg or < 90 mmHg, diastolic blood pressure> 100 mmHg or <50 mmHg
- Subjects who have had a history of drug abuse within one year of screening or have tested positive on urine drug screening test
- Pregnant or lactating women
- Subjects who have consistently excessively smoked or consumed caffeine or alcohol (caffeine:> 5 cups / day, alcohol:> 210 g / week, cigarettes:> 10 cigarettes / day) or cannot stop smoking, consuming caffeine and alcohol during hospitalization
Subjects who took any of the following drugs except for topical without serious systemic absorption and hormonal contraceptives and are deemed that the administered drug may affect in the study or the safety of the subject by the investigator
- Ethical-the-counter (ETC) drugs and herbal medicines within 14 days of the first administration of the investigational drug
- Over-the-counter (OTC) drugs, including health foods and vitamin preparations, within 7 days of the first dose of the investigational product
- Drugs administered by depot injection or through iomplantation in the human body within 30 days of the first dose of investigational product
- Subjects who have received the investigational product by participating in other clinical trials (including bioequivalence studies) within 180 days before the first dose of the investigational product (For biological agents, this may be based on a longer period of time, considering the half-life)
- Subjects who donated whole blood within 60 days before the first dose of the investigational product or donated component blood donation within 30 days
- Subjects who were deemed to be inappropriate to participate in the study by the investigator judgment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1
|
Test drug, QD, PO
Reference drug, QD, PO
|
Experimental: Group 2
|
Test drug, QD, PO
Reference drug, QD, PO
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax of D390 and CKD-375
Time Frame: 0(predose)~48 hours
|
Maximum plasma concentration of D390 and CKD-375
|
0(predose)~48 hours
|
AUClast of D390 and CKD-375
Time Frame: 0(predose)~48 hours
|
Area under the plasma concentration-time curve to last concentration of D390 and CKD-375
|
0(predose)~48 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUCinf of D390 and CKD-375
Time Frame: 0(predose)~48 hours
|
Area under the plasma concentration-time curve from zero to infinity concentration of D390 and CKD-375
|
0(predose)~48 hours
|
Tmax of D390 and CKD-375
Time Frame: 0(predose)~48 hours
|
Time to maximum plasma concentration of D390 and CKD-375
|
0(predose)~48 hours
|
t1/2 of D390 and CKD-375
Time Frame: 0(predose)~48 hours
|
Half-life of D390 and CKD-375
|
0(predose)~48 hours
|
Vd/F of D390 and CKD-375
Time Frame: 0(predose)~48 hours
|
Apparent volume of distribution of D390 and CKD-375
|
0(predose)~48 hours
|
CL/F of D390 and CKD-375
Time Frame: 0(predose)~48 hours
|
Apparent clearance of D390 and CKD-375
|
0(predose)~48 hours
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Min Soo Park, M.D., Ph.D., Severance Hospital
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- A92_02BE1920
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type2 Diabetes Mellitus
-
Mathias Ried-LarsenUnknownDiabetes Mellitus, Type 2 | Type 2 Diabetes Mellitus | Type2 Diabetes | Type2 Diabetes MellitusDenmark
-
Sigrid Therapeutics ABCompletedOverweight | PreDiabetes | Prediabetic State | Type2 Diabetes | Obese | Type2 Diabetes Mellitus | Pre DiabetesFinland, Sweden
-
Hamad Medical CorporationQatar Computing Research Institute (QCRI); Droobi HealthUnknown
-
Andalas UniversityUniversiti Putra MalaysiaCompleted
-
Medstar Health Research InstituteCompletedType2 Diabetes Mellitus
-
Boryung Pharmaceutical Co., LtdRecruiting
-
Georgia Institute of TechnologyNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Emory...CompletedType2 Diabetes MellitusUnited States
-
EMSWithdrawnType2 Diabetes Mellitus
-
TheracosCompletedType2 Diabetes MellitusUnited States
-
Chong Kun Dang PharmaceuticalUnknown
Clinical Trials on CKD-375
-
Chong Kun Dang PharmaceuticalUnknownType 2 Diabetes Mellitus
-
Optinose US Inc.RecruitingBilateral Nasal PolyposisUnited States
-
Optinose US Inc.CompletedChronic RhinosinusitisUnited States, United Kingdom, Bulgaria, Canada, Georgia, Poland, Russian Federation, Sweden
-
Optinose US Inc.CompletedChronic RhinosinusitisUnited States, Australia, Poland, New Zealand, Spain, Georgia, United Kingdom, Bulgaria, Czechia, Romania
-
Chong Kun Dang PharmaceuticalCompletedHealthyKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedHypertension | DyslipidemiasKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedAlopeciaKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedAlopeciaKorea, Republic of
-
Chong Kun Dang PharmaceuticalSeoul National University Bundang HospitalCompletedHealthyKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedHypertension and DyslipidemiaKorea, Republic of